Abstract: The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.
| # | Name | Date |
|---|---|---|
| 1 | 202147047514-STATEMENT OF UNDERTAKING (FORM 3) [20-10-2021(online)].pdf | 2021-10-20 |
| 2 | 202147047514-SEQUENCE LISTING(PDF) [20-10-2021(online)].pdf | 2021-10-20 |
| 3 | 202147047514-SEQUENCE LISTING [20-10-2021(online)].txt | 2021-10-20 |
| 4 | 202147047514-PRIORITY DOCUMENTS [20-10-2021(online)].pdf | 2021-10-20 |
| 5 | 202147047514-POWER OF AUTHORITY [20-10-2021(online)].pdf | 2021-10-20 |
| 6 | 202147047514-FORM 18 [20-10-2021(online)].pdf | 2021-10-20 |
| 7 | 202147047514-FORM 1 [20-10-2021(online)].pdf | 2021-10-20 |
| 8 | 202147047514-DECLARATION OF INVENTORSHIP (FORM 5) [20-10-2021(online)].pdf | 2021-10-20 |
| 9 | 202147047514-COMPLETE SPECIFICATION [20-10-2021(online)].pdf | 2021-10-20 |
| 10 | 202147047514.pdf | 2021-10-23 |
| 11 | 202147047514-Proof of Right [27-12-2021(online)].pdf | 2021-12-27 |
| 12 | 202147047514-FORM 3 [14-04-2022(online)].pdf | 2022-04-14 |
| 13 | 202147047514-FORM 3 [12-10-2022(online)].pdf | 2022-10-12 |
| 14 | 202147047514-RELEVANT DOCUMENTS [15-12-2022(online)].pdf | 2022-12-15 |
| 15 | 202147047514-POA [15-12-2022(online)].pdf | 2022-12-15 |
| 16 | 202147047514-FORM 13 [15-12-2022(online)].pdf | 2022-12-15 |
| 17 | 202147047514-FORM 3 [07-04-2023(online)].pdf | 2023-04-07 |
| 18 | 202147047514-POA [20-10-2023(online)].pdf | 2023-10-20 |
| 19 | 202147047514-FORM 13 [20-10-2023(online)].pdf | 2023-10-20 |
| 20 | 202147047514-AMENDED DOCUMENTS [20-10-2023(online)].pdf | 2023-10-20 |
| 21 | 202147047514-FORM 3 [01-12-2023(online)].pdf | 2023-12-01 |